236 related articles for article (PubMed ID: 31648983)
1. Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
Alcala N; Mangiante L; Le-Stang N; Gustafson CE; Boyault S; Damiola F; Alcala K; Brevet M; Thivolet-Bejui F; Blanc-Fournier C; Le Rochais JP; Planchard G; Rousseau N; Damotte D; Pairon JC; Copin MC; Scherpereel A; Wasielewski E; Wicquart L; Lacomme S; Vignaud JM; Ancelin G; Girard C; Sagan C; Bonnetaud C; Hofman V; Hofman P; Mouroux J; Thomas de Montpreville V; Clermont-Taranchon E; Mazieres J; Rouquette I; Begueret H; Blay JY; Lantuejoul S; Bueno R; Caux C; Girard N; McKay JD; Foll M; Galateau-Salle F; Fernandez-Cuesta L
EBioMedicine; 2019 Oct; 48():191-202. PubMed ID: 31648983
[TBL] [Abstract][Full Text] [Related]
2. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in malignant pleural mesothelioma.
Davidson B
Hum Pathol; 2015 Jun; 46(6):789-804. PubMed ID: 25824607
[TBL] [Abstract][Full Text] [Related]
5. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
6. [Malignant pleural mesothelioma].
Sritharan SS; Frandsen JL; Omland Ø; Bruun JM
Ugeskr Laeger; 2018 Apr; 180(15):. PubMed ID: 29690982
[TBL] [Abstract][Full Text] [Related]
7. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
[TBL] [Abstract][Full Text] [Related]
8. Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.
Meiller C; Montagne F; Hirsch TZ; Caruso S; de Wolf J; Bayard Q; Assié JB; Meunier L; Blum Y; Quetel L; Gibault L; Pintilie E; Badoual C; Humez S; Galateau-Sallé F; Copin MC; Letouzé E; Scherpereel A; Zucman-Rossi J; Le Pimpec-Barthes F; Jaurand MC; Jean D
Genome Med; 2021 Jul; 13(1):113. PubMed ID: 34261524
[TBL] [Abstract][Full Text] [Related]
9. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
11. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
Smeele P; d'Almeida SM; Meiller C; Chéné AL; Liddell C; Cellerin L; Montagne F; Deshayes S; Benziane S; Copin MC; Hofman P; Le Pimpec-Barthes F; Porte H; Scherpereel A; Grégoire M; Jean D; Blanquart C
Mol Cancer; 2018 Oct; 17(1):148. PubMed ID: 30309369
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.
Angelico G; Caltabiano R; Loreto C; Ieni A; Tuccari G; Ledda C; Rapisarda V
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495596
[TBL] [Abstract][Full Text] [Related]
13. Chemokines involved in the early inflammatory response and in pro-tumoral activity in asbestos-exposed workers from an Italian coastal area with territorial clusters of pleural malignant mesothelioma.
Comar M; Zanotta N; Zanconati F; Cortale M; Bonotti A; Cristaudo A; Bovenzi M
Lung Cancer; 2016 Apr; 94():61-7. PubMed ID: 26973208
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
[TBL] [Abstract][Full Text] [Related]
15. Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value.
Shaker N; Wu D; Abid AM
Diagn Cytopathol; 2022 Nov; 50(11):532-537. PubMed ID: 36069384
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Kondola S; Manners D; Nowak AK
Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
19. Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues.
Markowitz S
Semin Respir Crit Care Med; 2015 Jun; 36(3):334-46. PubMed ID: 26024342
[TBL] [Abstract][Full Text] [Related]
20. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
